Fennec Pharmaceuticals Inc. (FENC) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Fennec Pharmaceuticals reported revenue of $44.6M, down 6.1% from $47.5M the year before. Net income was -$9.7M (a -21.8% net margin), or -$0.34 per diluted share. Operating margin was -14.1%. Operating activities generated -$12.5M of cash. At fiscal year end, Fennec Pharmaceuticals held $70.6M in total assets against $35.1M in total liabilities, including $36.8M of cash and equivalents.
Open the full interactive Fennec Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Fennec Pharmaceuticals Key Stats
| Share Price | $10.18 |
|---|---|
| Market Cap | $370.9M |
| Revenue YoY Growth | -6.1% |
| 52-Week Range | $5.77 – $12.78 |
| Shares Outstanding | 34.5 million (basic, 2026 Q2) |
Fennec Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.5M | $21.3M | $47.5M | $44.6M |
| Cost of Goods Sold | — | — | $86,000 | $1.3M | — | — |
| Gross Profit | — | — | $1.4M | $20.0M | — | — |
| Operating Income | -$17.9M | -$17.2M | -$22.6M | -$12.8M | $2.6M | -$6.3M |
| Pre-Tax Income | -$18.1M | -$17.3M | -$23.7M | -$16.0M | -$71,000 | -$9.6M |
| Income Tax | $0 | $0 | $0 | — | $365,000 | $106,000 |
| Net Income | -$18.1M | -$17.3M | -$23.7M | -$16.0M | -$436,000 | -$9.7M |
| Diluted EPS | -$0.76 | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 |
Fennec Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $12.5M | $13.8M | $15.1M | $17.9M |
| Net Income | -$638,000 | -$4.8M | $201,000 | $2.0M |
| Diluted EPS | -$0.02 | -$0.17 | $0.01 | $0.05 |
Fennec Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.3M | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Current Assets | $31.4M | $22.4M | $26.7M | $26.9M | $44.1M | $67.0M |
| Total Assets | $31.4M | $22.4M | $26.9M | $26.9M | $44.9M | $70.6M |
| Current Liabilities | $2.3M | $1.7M | $4.6M | $7.6M | $6.9M | $10.5M |
| Total Long-Term Debt | — | — | $24.9M | $30.9M | $19.3M | — |
| Total Liabilities | $2.3M | $6.6M | $29.5M | $38.5M | $50.8M | $35.1M |
| Shareholders' Equity | $29.1M | $15.8M | -$2.6M | -$11.6M | -$5.9M | $35.5M |
Fennec Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.6M | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Cash From Financing | $32.3M | $5.0M | $20.7M | $6.6M | -$13.6M | $22.6M |
Figures from Fennec Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fennec Pharmaceuticals financials page for every line item.
Fennec Pharmaceuticals Company Profile
| Ticker | FENC |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Research Triangle Park, North Carolina |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001211583 |
Frequently Asked Questions
What was Fennec Pharmaceuticals' revenue in fiscal 2025?
Fennec Pharmaceuticals (FENC) reported revenue of $44.6M for fiscal 2025.
What is Fennec Pharmaceuticals' annual revenue history?
Fennec Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $1.5M; 2023: $21.3M; 2024: $47.5M; 2025: $44.6M.
What was Fennec Pharmaceuticals' net income in fiscal 2025?
Fennec Pharmaceuticals reported net income of -$9.7M for fiscal 2025.
What was Fennec Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Fennec Pharmaceuticals' diluted EPS was -$0.34 for fiscal 2025 (adjusted for any later stock splits).
What was Fennec Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Fennec Pharmaceuticals reported revenue of $17.9M.
How many shares of Fennec Pharmaceuticals are outstanding?
Fennec Pharmaceuticals reported a weighted average of 34.5 million basic shares outstanding in 2026 Q2.
What is Fennec Pharmaceuticals' market cap?
Based on its latest closing price, Fennec Pharmaceuticals (FENC) has a market capitalization of about $370.9M.
When does Fennec Pharmaceuticals' fiscal year end?
Fennec Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Fennec Pharmaceuticals headquartered?
Fennec Pharmaceuticals lists its business address in Research Triangle Park, North Carolina in its SEC filings.
Fennec Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →